Lymphoma Clinical Trials

Showing 461-480 of 2,926 trials

CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)

NCT06420089

This is an open-label phase I study to determine the safety and recommended phase 2 dose (RP2D) of Senza5 CART5 cells in patients with relapsed or refractory CD5 positive nodal T cell NHL. RP2D will be based on the safety, tolerability, pharmacokinetics, and preliminary efficacy of Senza5 CART5 cells. This trial will evaluate up to 5 dose levels using the Bayesian Optimal Interval (BOIN) design enrolling 3 patients in each cohort to assess safety and achieve therapeutic levels so that the RP2D of Senza5 CART5 cells given as a single IV infusion can be determined.

T Cell Non-Hodgkin Lymphoma

Vittoria Biotherapeutics30 participantsStarted Oct 2024

New York, New York, United States • Philadelphia, Pennsylvania, United States

Active Not RecruitingPhase 1

Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma

NCT01209871

This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with lymphoplasmacytic lymphoma. Vaccines made from a person's cancer cells may help the body build an effective immune response to kill cancer cells.

Lymphoplasmacytic Lymphoma

M.D. Anderson Cancer Center9 participantsStarted Feb 2015

Houston, Texas, United States

Active Not RecruitingPhase 1

huCART19-IL18 in CD19+ Cancers

NCT04684563

The purpose of this study is to evaluate the safety and feasibility of huCART19-IL18 cells in patients with relapsed or refractory CD19+ cancers.

Chronic Lymphocytic LeukemiaNon-hodgkin LymphomaAcute Lymphoblastic Leukemia

University of Pennsylvania72 participantsStarted May 2021

Philadelphia, Pennsylvania, United States

CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)

Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma

huCART19-IL18 in CD19+ Cancers

Related Searches

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy

Auto Stem Cell Transplant for Lymphoma Patients

A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)

DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas

Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study

Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas

Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)

Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta)

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)

A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)

Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)

Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma

Resiliency in Older Adults Undergoing Bone Marrow Transplant

To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL